Olanzapine induced rhabdomyolysis and serum creatine kinase increase;Rhabdomyolyse et élévation des enzymes musculaires sous olanzapine

Revue de Medecine Interne

Volumn 30, Issue 6, 2009, Pages 477-485

  Ribeyron, S ^a   Guy, C ^b   Koenig, M ^b   Cathebras P ^b  

^a UNIVERSITÉ JEAN MONNET   (France)

^b HÔPITAL NORD   (France)

Author keywords

"Atypical" antipsychotics; Adverse drug reactions; Muscle enzyme; Olanzapine; Rhabdomyolysis

Indexed keywords

OLANZAPINE;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FEMALE; HOSPITALIZATION; HUMAN; MALE; MEDICAL LITERATURE; OUTCOME ASSESSMENT; RHABDOMYOLYSIS; SIDE EFFECT;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CREATINE KINASE; FEMALE; HUMANS; MALE; MIDDLE AGED; RHABDOMYOLYSIS;

EID: 67349163873     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2008.12.024     Document Type: Article

References (21)

1. Llorca P.M. Les antipsychotiques. In: Guelfi J.D., and Rouillon F. (Eds). Manuel de psychiatrie (2007), Masson, Paris 524-535
2. Fratta A., Gury C., and Petitjean F. Olanzapine dans le traitement de la schizophrénie. Évaluation clinique. Dossiers du Centre national hospitalier d'information sur le médicament vol. 23 (2002), CNHIM 5-35
3. ®). Presse Med 29 (2000) 2106-2108
4. Koenig M., Burnot A., Bosacki C., Guy C., Ratrema M., and Cathébras P. Camptocormie, rhabdomyolyse aiguë, et olanzapine : à propos de 2 cas. Rev Med Interne 28 suppl.4 (2007) S518
5. Les rhabdomyolyses. Entre simples douleurs musculaires et insuffisance rénale aiguë. Prescrire 2003;23:537-9.
6. e édition, texte révisé (Washington DC; 2000). Paris: Masson; 2003.
7. Kogoj A., and Velikonja I. Olanzapine induced neuroleptic malignant syndrome - a case review. Hum Psychopharmacol 18 (2003) 301-309
8. Farver D.K. Neuroleptic malignant syndrome induced by atypical antipsychotics. Expert Opin Drug Saf 2 (2003) 21-35
9. Croarkin P.E., Emslie G.H., and Mayes T.L. Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. J Clin Psychiatry 69 (2008) 1157-1165
10. Begaud B., Evreux J.C., Jouglard J., and Lagier G. Imputabilité des effets inattendus ou toxiques des médicaments. Actualisation de la méthode utilisée en France. Therapie 40 (1985) 111-118
11. Marcus E.L., Vass A., and Zislin J. Marked elevation of serum creatine kinase associated with olanzapine therapy. Ann Pharmacother 33 (1999) 697-700
12. Rosebraught C.J., Flockhart D.A., Yasuda S.U., and Woosley R.L. Olanzapine-induced rhabdomyolysis. Ann Pharmacother 35 (2001) 1020-1023
13. Marti-Bonmati E., Valero-Carcelen E., Ortega-Garcia M.P., and Rubini-Puig R. Olanzapine elevation of serum creatine kinase. J Clin Psychiatry 64 (2003) 483-484
14. Baumgart U., Schmid R., and Spieβl H. Olanzapine-induced acute rhabdomyolysis: a case report. Pharmacopsychiatry 38 (2005) 36-37
15. Perlov E., Tebarsz Van Elst L., Czygan M., Bubl E., and Ebert D. Serum creatine kinase as a possible complication of therapy with olanzapine. Naunyn Schmiedebergs Arch Pharmacol 372 (2005) 168-169
16. Devarajan S., and Dursun S.M. Antipsychotic drugs, serum creatine kinase (CPK) and possible mechanisms. Psychopharmacology (Berl) 152 (2000) 122
17. Boot E., and de Haan L. Massive increase in serum creatine kinase during olanzapine and quietapine treatment, not during treatment with clozapine. Psychopharmacology (Berl) 150 (2000) 347-348
18. Conley R.R., and Kelly D.L. Second-generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effects. Isr J Psychiatry Relat Sci 42 (2005) 51-60
19. Meltzer H.Y., Cola P.A., and Parsa M. Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment. Neuropsychopharmacology 15 (1996) 395-405
20. Waring W.S., Wrate J., and Bateman D.N. Olanzapine overdose is associated with acute muscle toxicity. Hum Exp Toxicol 25 (2006) 735-740
21. Meltzer H.Y. Massive serum creatine kinase increases with atypical antipsychotic drugs: what is the mechanism and the message?. Psychopharmacology 150 (2000) 349-350